Optimal primary therapy of ovarian cancer: Table 1.

Why have ovarian cancer mortality rates declined? Part II. Case-fatality

(2015) Victoria Sopik et al.   GYNECOLOGIC ONCOLOGY

Why have ovarian cancer mortality rates declined? Part I. Incidence

(2015) Victoria Sopik et al.   GYNECOLOGIC ONCOLOGY

Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions

(2015) Johnathan M. Lancaster et al.   GYNECOLOGIC ONCOLOGY

Does Aggressive Surgery Improve Outcomes? Interaction Between Preoperative Disease Burden and Complex Surgery in Patients With Advanced-Stage Ovarian Cancer: An Analysis of GOG 182

(2015) Neil S. Horowitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

(2015) Devansu Tewari et al.   JOURNAL OF CLINICAL ONCOLOGY

Better Therapeutic Trials in Ovarian Cancer

(2014) M. A. Bookman et al.   JNCI-Journal of the National Cancer Institute

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

(2014) Sandro Pignata et al.   LANCET ONCOLOGY

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

(2013) Noriyuki Katsumata et al.   LANCET ONCOLOGY

The Role of Intraoperative Radiation Therapy in the Management of Recurrent and Locally Advanced Gynecologic Cancers

(2012) Olivia W. Foley et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study

(2011) Robert S. Mannel et al.   GYNECOLOGIC ONCOLOGY

The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study

(2009) John K. Chan et al.   GYNECOLOGIC ONCOLOGY